Ticker

HIGHLIGHTS New patent application published covering chemically novel FAK inhibitors discovered by Amplia Application expands Amplia's intellectual property portfolio supporting its FAK inhibitor program If granted, patent protection for the new molecules and their use would extend to 2046 New compounds broaden pipeline optionality and may support future development and partnering opportunities Melbourne, Australia,…

Melbourne, Australia, July 07, 2026 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX, OTCQB:INNMF), (“Amplia” or the “Company”), is pleased to announce the appointment of Mr Brett Carter to the Board of Directors as non-executive director, effective from 6 July 2026.

Melbourne, Australia, July 06, 2026 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX, OTCQB:INNMF), (“Amplia” or the “Company”), announces Board changes further to a Board renewal and succession plan.

Melbourne, Australia, June 22, 2026 (GLOBE NEWSWIRE) -- Amplia Therapeutics Limited (ASX:ATX | OTCQB:INNMF), (“Amplia” or the “Company”) provides a letter to shareholders from CEO and Managing Director Dr. Chris Burns outlining the potential for the Company's best-in-class FAK inhibitor narmafotinib in combination with the emerging KRAS inhibitor class following exciting new data presented at the American Society of…

HIGHLIGHTS New Phase 2b study builds on compelling Phase 1b/2a ACCENT study data to lay foundation for Phase 3 registrational study Focus on investigating new, daily dosing of narmafotinib in combination with standard regimen of gemcitabine and Abraxane in patients with advanced pancreatic cancer Accelerated initiation made possible by clinic-ready drug product and resources transitioned from AMPLICITY study Patient…